Genelux CORP

Genelux Corporation has entered into a Sales Agreement with TD Cowen to offer and sell up to $100 million of its common stock through an at-the-market offering.

Genelux Corporation announced an updated corporate presentation detailing recent business and strategic developments.

Genelux Corporation announced the pricing of an underwritten public offering of 6.67 million common shares at $3.00 each, aiming to raise $20.0 million for general corporate purposes, including R&D and clinical trials.

Genelux Corporation announced encouraging interim results from two ongoing trials evaluating systemic administration of Olvi-Vec in patients with progressive small cell lung cancer and non-small cell lung cancer.

Genelux Corporation announced the immediate resignation of Dr. Paul Scigalla as Chief Medical Officer and the appointment of Dr. Jason Litten to the role, effective January 2, 2026.

Genelux Corporation announced a reduction in the exercise price of certain employee stock options to $3.33 per share and reported the results of its 2025 Annual Meeting of Stockholders, including the election of two Class III directors and the ratification of its independent auditor.

Genelux Corporation reported increased net losses and cash burn in Q3 2025, with existing capital projected to fund operations only into the third quarter of 2026, raising substantial doubt about its going concern ability.

Genelux Corporation reported increased net losses and a going concern warning, despite progress in clinical trials and a recent $9.6 million capital raise.

Genelux Corporation reports a net loss of $7.5 million for Q1 2025, but extends its cash runway into the third quarter of 2026 following a public offering.

Genelux Corporation's third quarter 2024 report shows a net loss of $6.467 million, with ongoing clinical trial advancements and a cash runway extended into the first quarter of 2026.

Genelux Corporation's second quarter 2024 results show a net loss of $14.4 million, but the company's cash runway is extended into the first quarter of 2026 due to recent public offerings.

Genelux Corporation announced its financial results for the first quarter of 2024, highlighting a net loss of $7.85 million and ongoing clinical trial activities.

Genelux Corporation reported increased net losses for 2025 but extended its cash runway into the first quarter of 2027 following recent capital raises, while advancing its oncolytic viral immunotherapy pipeline.

Genelux Corporation files an amendment to its annual report on Form 10-K to include Part III information regarding directors, executive officers, and corporate governance.

Genelux Corporation's 10-K filing highlights its focus on developing oncolytic viral immunotherapies, particularly Olvi-Vec, for aggressive solid tumors, and outlines its clinical development strategy, manufacturing capabilities, and financial position.

Genelux Corporation's 2023 annual report details the company's financial status, clinical trial progress, and strategic initiatives in developing oncolytic viral immunotherapies.

Yong Yu, Chief Scientific Officer of GENELUX Corp, sold 653 shares of common stock on August 4, 2026 for $2.94 per share.

Joseph Cappello, Chief Technical Officer of GENELUX Corp, sold 653 shares of common stock on August 4, 2026 for $2.95 per share.

Thomas Zindrick, President and CEO of GENELUX Corp, sold 3,023 shares of common stock on August 4, 2026 for $2.95 per share.

John W. Smither, a Director at GENELUX Corp, reported a sale of 12,000 common shares on July 1, 2026, for tax coverage purposes.

GENELUX Corp. Chief Financial Officer Matthew Pulisic acquired 278,906 shares of common stock through restricted stock units.

Genelux Corp reports the grant of restricted stock units to General Counsel Eric Groen, with vesting scheduled over four years.

Genelux Corporation has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect a director and ratify auditor.

Genelux Corporation has filed a Definitive Proxy Statement (DEFA14A) with the U.S. Securities and Exchange Commission.

Genelux Corporation announced its 2025 Annual Meeting of Stockholders will be held virtually on August 27, 2025, to vote on the election of two Class III directors and the ratification of its independent registered public accounting firm.

Genelux Corporation has filed a definitive proxy statement with the SEC.

Genelux Corporation will hold its 2024 Annual Meeting of Stockholders virtually on August 1, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in GENELUX Corp, totaling 4,223,277 shares of common stock.

Aladar Szalay has filed an amended Schedule 13G, reporting beneficial ownership of 8.4% of Genelux Corporation's common stock as of June 30, 2025.